Topics

Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 18/10/2009, Revision: 9, Status: Auth

12:22 EST 4 Dec 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 18/10/2009, Revision: 9, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 18/10/2009, Revision: 9, Status: Auth

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 18/10/2009, Revision: 9, Status: Auth"

Quick Search

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Influenza
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...